Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$151.02 +0.31%

+$0.46 today

Market cap
$6.08B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.14M

Average 0.17M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$36.99M

FY 2025 · Annual

Investing Cash Flow

-$305.11M

FY 2025 · Annual

Financing Cash Flow

$663.23M

FY 2025 · Annual

+693.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.67M)(12.65M)(31.63M)(36.14M)(77.61M)
Depreciation & Amortization30K198K399K449K464K
Deferred Income Tax0(1.91M)(4.69M)00
Stock-Based Compensation1.53M1.48M3.82M8.99M38.92M
Change in Working Capital640K(491K)(2.43M)1.13M2.55M
Accounts Receivables0(32K)(72K)74K(66K)
Inventory00000
Accounts Payables00000
Other Working Capital640K(459K)(2.36M)1.06M2.62M
Other Non-Cash Items(8K)1.91M4.69M(3.66M)(1.31M)
Operating Cash Flow(7.47M)(11.46M)(29.84M)(29.23M)(36.99M)
Capital Expenditures(74K)(394K)(63K)(151K)(178K)
Acquisitions (Net)18K0000
Purchases of Investments000(188.27M)(451.99M)
Sales of Investments00077.84M147.07M
Other Investing Activities000(35K)0
Investing Cash Flow(56K)(394K)(63K)(110.57M)(305.11M)
Debt Repayment00000
Common Stock Issued(583K)37.99M77.19M42.24M292.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(1.03M)(1.23M)41.36M370.37M
Financing Cash Flow(583K)36.96M75.96M83.6M663.23M
Effect of Forex Changes(161K)(366K)9K(269K)117K
Net Change in Cash(8.27M)24.75M46.07M(56.48M)321.26M
Free Cash Flow(7.55M)(11.85M)(29.9M)(29.39M)(37.17M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$77.6M
+ D&A$464.0K
+ Stock-Based Comp$38.9M
+ Deferred Tax$0
+ Working Capital$2.6M
- Other Non-Cash-$1.3M
= Operating Cash Flow-$37.0M
- Capex-$178.0K
= Free Cash Flow-$37.2M

Analysis

FY2025 free cash flow is -$37.2M. FCF conversion is 47.9% of net income. Operating cash flow was -$37.0M, with capex of -$178.0K. The largest bridge item is Stock-Based Comp at $38.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
6-K6-K filingOct 19, 2026

Does BLTE generate free cash flow?

Belite Bio, Inc (BLTE) generated -$37.17M of free cash flow in fiscal 2025.

How much operating cash flow does BLTE produce?

Operating cash flow was -$36.99M, before capital expenditures of $178,000.00.